Q J Med 2000; 93: 203-205
© 2000 Association of Physicians
Editorial |
Controlling hypertension in the elderly
Care of the Elderly, Imperial College School of Medicine, Hammersmith Campus, London
Hypertension is best defined as the level of blood pressure above which treatment does more good than harm. This information comes from the results of randomized controlled trials, i.e. the evidence base. However, we do not know the level of blood pressure at which treatment fails to confer an overall benefit. Such a level is predicted to exist, as at lower levels of blood pressure, few gain by having cardiovascular events prevented yet all are at risk of the adverse effects of treatment. At the beginning of 2000, we know that at most ages it is worth treating a systolic blood pressure 
160 mmHg and/or a diastolic blood pressure 90 mmHg. This has not prevented speculation that treatment should be started at say, a systolic pressure of 140–159 mmHg.1,2 Nevertheless caution must be expressed that adverse effects may outweigh advantages in certain groups, for example the very elderly (>80 years) and those whose blood pressure is high when lying but low on standing. The same may apply to those with a high blood pressure when first seen but normal pressures thereafter; although transient hypertension, at least in men, still confers an excess cardiovascular risk.3 Obviously we should consider the over-80s further, assess blood pressure in the standing position, and determine the sustained level of blood pressure.
At age 65–79 years, experimental evidence suggests that a sustained systolic pressure 160 mmHg should be treated irrespective of diastolic blood pressure.4,5 It is also probable (but not proven) that a diastolic pressure of 90 mmHg should be treated irrespective of systolic pressure.6 The pressure should be measured at least three times on separate occasions over a period of time. The period of time should be at least 2 months, to agree with the evidence from the trials, and the blood pressure should be taken in the sitting position but with a standing systolic pressure of at least 140 mmHg.5 Thus we have an evidence base for treatment in subjects under age 80, but having decided on ‘treatment’, what should this be and what constitutes ‘control’ of hypertension?
Unlike the level of pressure at which we should treat, the level of blood pressure that we should achieve with treatment is unknown. For systolic pressure, there are no randomized controlled trial data. Epidemiological data suggest that levels of 125 mmHg should be achieved,7 but the guidelines are more conservative, suggesting <140 mmHg.1,2 For diastolic blood pressure, the Hypertension Optimum Treatment (HOT) trial randomized patients to achieve a diastolic blood pressure of <90 mmHg, <85 mmHg or <80 mmHg.8 In the event, the achieved blood pressures averaged 85.2, 83.2 and 81.1 mmHg for the three groups, respectively. Cardiac and stroke events did not differ with statistical significance between the three groups. The epidemiological data suggest that diastolic pressure should not be lowered below 85 mmHg, because of the J-shaped curve where ischaemic heart disease (IHD) mortality increases with a treated diastolic blood pressure of 
85 mmHg. However, the HOT trial does not support this and in the Systolic Hypertension in the Elderly Program (SHEP) trial, cardiac deaths were reduced when diastolic pressure was lowered from an average of 77 mmHg to 68 mmHg, albeit in the presence of a high systolic pressure.4 Most researchers have concluded that the J-shaped increase in mortality at lower pressure is not produced by the pressure, rather that the lower pressure is induced by coronary disease.9
In the HOT trial, systolic pressure was reduced from an average of 170 mmHg to 140–144 mmHg. In the European Working Party on High blood Pressure in the Elderly (EWPHE), SHEP and Systolic Hypertension in Europe (Syst-Eur) trials systolic pressures were reduced from means of 183, 170 and 174 mmHg, to 149, 144 and 151 mmHg, respectively.4–6 In these trials, the goal blood pressure was 140–160 mmHg (not 125 mmHg!) and even so about 30–50% of patients failed to achieve goal blood pressure. Moreover, this effect required two or more anti-hypertensive drugs in more than 40% of patients. We must conclude that with today's pharmacological treatments, we are unlikely to reach ‘low’ goal pressures. Side-effects must be avoided, for example postural hypotension. The latter may be a greater problem in the elderly and be compounded by postprandial hypotension. These side-effects will certainly limit the numbers achieving goal blood pressure, even if assessed in the standing position, and may increase the default rates on treatment. In theory, we may strive to lower systolic pressure to below 125 mmHg and diastolic pressure to below 80 mmHg but in practice, especially in the elderly, we are likely to be disappointed. A possible pragmatic rule, valid only at the time of writing, is that the goal blood pressure in the elderly should be ‘a standing systolic pressure <140 mmHg and diastolic <80 mmHg’.
The evidence base for non-pharmacological treatments in the very elderly is very sparse, but unless the patient consumes large amounts of alcohol and stops, is grossly overweight and loses weight, or greatly reduces sodium intake, large reductions in pressure are unlikely. My personal view is that smoking must be stopped and that may require firm advice, nicotine patches or inhaler (the gum is difficult with false teeth), hypnotherapy or acupuncture. Ignore comments such as ‘grandfather's sole remaining pleasure’ and ‘he will not live long enough to benefit’—if his expectation of life is so short, we are not going to treat his hypertension! Having dealt with smoking, the concepts of abstinence from alcohol, weight loss, sodium reduction and exercise may be introduced but expect to give drug treatment in the end. After all the rule of halves or (hopefully) thirds is still with us; if one third of hypertensives are unknown, one third of these are untreated and one third of these uncontrolled, then only 30% have good blood pressure control. We must be careful not to frighten patients away with difficult diets (low salt plus low sugar plus low fat plus high fibre) and to avoid side-effects if possible.
Assuming we have agreed on a goal pressure, how is it to be achieved? The selection of an anti-hypertensive drug has had more to do with marketing than science, but a new generation of trials have been designed that compare the different drugs in terms of morbidity and mortality outcomes. It is expected that these trials will provide valuable information. The forerunners of the modern trials comparing active treatments were the Medical Research Council (MRC) trials where patients were randomized 2 : 1 : 1 to placebo, diuretic and beta-blocker treatment.10,11 In the MRC trial in the elderly, patients treated with a beta-blocker fared badly,11 leading to the suggestion that beta-blockers should be avoided in this age group.12,13 However the STOP (Swedish Trial in Old Patients)-hypertension-2 trial has recently reported in which beta-blocker±diuretic treatment was compared with calcium channel blocker±beta blocker and angiotensin-converting-enzyme (ACE) inhibitor±diuretic treatment.14 No disadvantage was found for a beta-blocker. Two further trials are in progress to compare different treatments, ALLHAT and ASCOT, but in the meantime the drug employed would not appear very important. Obviously there are contra-indications, and these must be adhered to, similarly side-effects and quality-of-life issues may determine choice of drug. Some drugs are popularly used in certain circumstances, for example ACE inhibitors in diabetics. However, low-dose diuretics are inexpensive and successful, even in diabetic patients,15 as are calcium-channel blockers.16 The important consideration is to avoid specific drugs in certain conditions, e.g. beta blockers in asthmatics, calcium channel blockers in heart failure, diuretics in gout, and find the drug or combination of drugs that achieve goal blood pressure.
In the very elderly, over the age of 80, the picture is more confusing. First the epidemiology suggest that the higher the blood pressure, the lower the mortality,17 and second, there is currently no evidence base from randomized trials to support treatment. The epidemiological findings, for the elderly population as a whole, appear well substantiated, but this inverse relationship between blood pressure and mortality may simply be an extension of the J-shaped curve. In the over-80s, subjects with a low blood pressure may not only include those with a fibrotic myocardium following myocardial infarction, but those who have lost weight through cancer, dementia and other illnesses. No surprise, perhaps, that those with a high blood pressure are the fittest and survive well. Nevertheless, we need to know whether, with treatment, these fit subjects will live even longer. No trial, with the exception of the Hypertension in the Very Elderly (HYVET) pilot trial18 has been specifically targeted at the over-80s, however, a meta-analysis of subjects over the age of 80 entered into other trials showed some intriguing results. Strokes (fatal plus non-fatal) appeared to be reduced by active treatment, whereas total mortality tended to be increased.19 As discussed, there must be a blood pressure, or age (or some combination of pressure and age) that is not worth treating because the adverse effects outweigh the benefits. The problem of providing evidence for or against treatment is being addressed in the main HYVET trial. In the meantime, whom shall we treat? Firstly, severe hypertension is excluded from the HYVET trial, and systolic pressure of 200 mmHg or diastolic pressure 110 mmHg deserve treatment in the absence of an evidence base. Others exclusions indicate whom to treat: those with any degree of heart failure, angina, renal failure or (rarely) evidence of accelerated hypertension. For other patients, if you treat them they may avoid a stroke but not necessarily live any longer. The optimist may assume that, as all placebo-controlled trials in hypertension have shown overall benefit, so will trials in the very elderly; The pessimist, always wrong in the past, may not wish to provide pharmacological intervention to fit survivors, many who have had mild hypertension tracking upwards for decades, without adverse consequences as yet.
References
1.
Ramsay LE, Williams B, Johnston GD, MacGregor GA, Poston L, Potter JF, Poulter NR, Russell G. British Hypertension Society guideline for hypertension management 1999: summary. Br Med J1999; 319:630–5.
2. Guidelines Subcommittee. 1999 World Health Organization—International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens1999; 17:151–83.[ISI][Medline]
3.
Fletcher AE, Bradley IC, Broxton JS, Bulpitt CJ, Davis AJ, Dyker GS, Ganvir PL, Gostick NK, Mayhew SR, Mukerji D, Newberry DJ, Palmer AJ, Shepherd F, Wells FO. Survival of hypertensive subjects identified on screening: results for sustained and unsustained diastolic hypertension. Eur Heart J1992; 13:1595–601.
4. SHEP Co-operative Research Group. Prevention of Stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the systolic hypertension in the elderly program (SHEP). JAMA1991; 265:3255–64.[Abstract]
5. Staessen JA, Fagard R, Thijs L, Celis H, Arabidze GG, Birkenhager WH, Bulpitt CJ, de Leeuw PW, Dollery CT, Fletcher AE, Forette F, Leonetti G, Nachev C, O'Brien ET, Rosenfeld J, Rodicio JL, Tuomilehto J, Zanchetti A, for the SYST-EUR trial investigators. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. Lancet1997; 350:757–64.[ISI][Medline]
6. Amery A, Birkenhager W, Brixko P, Bulpitt CJ, Clement D, Deruyttere M, de Schaepdriyver A, Dollery CT, Fagard R, Forette F, Forte K, Hamdy R, Henry JF, Joossens JV, Leonetti G, Lund-Johansen P, O'Malley K, Petrie J, Strasser T, Tuomilehto J, Williams B. Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly. Lancet1985; i:1349–54.
7. Fletcher AE, Bulpitt CJ. How far should blood pressure be lowered? N Engl J Med1992; 326:251–4.[ISI][Medline]
8. Hansson L, Zanchetti A, Carruthers SG, Dahlöf B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S, for the HOT Study Group. Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet1998; 351:1755–62.[ISI][Medline]
9. Kaplan N. J-curve not burned off by HOT study. Lancet1998; 351:1748–9.[ISI][Medline]
10. Medical Research Council Working Party. MRC trial of treatment of mild hypertension: principal results. Br Med J1985; 291:97–104.
11. MRC Working Party. Medical Research Council trial of treatment of hypertension in older adults: principal results. Br Med J1992; 304:405–12.
12.
Messerli FH, Grossman E, Goldbourt U. Are ß-blockers efficacious as first-line therapy for hypertension in the elderly? A systematic review. JAMA1998; 279:1903–7.
13. Psaty BM, Smith NL, Siscovick DS, Koepsell TD, Weiss NS, Heckbert SR, et al. Health outcomes associated with antihypertensive therapies used as first-line agents. A systematic review and meta analysis. JAMA1997; 277:739–45.[Abstract]
14. Hansson L, Lindholm LH, Ekbom T, Dahlöf B, Lanke J, Schersten B, Wester PO, Hedner T, de Fair U, for the STOP-Hypertension-2 Study group. Randomised trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity—the Swedish Trial in Old Patients with Hypertension—2 study. Lancet1999; 354:1751–6.[ISI][Medline]
15. Curb JD, Pressel SL, Cutler JA, Savage PJ, Applegate WB, Black H, Camel G, Davis BR, Frost PH, Gonzalez N, Guthrie G, Oberman A, Rutan GH, Stamler J. Effect of diuretic-based antihypertensive treatment on cardiovascular disease risk in older diabetic patients with isolated systolic hypertension. Systolic Hypertension in the Elderly Program Cooperative Research Group. JAMA1996; 276:1886–92.[Abstract]
16.
Tuomilehto J, Rastentyte D, Birkenhager W, Thijs L, Antikainen R, Bulpitt CJ, Fletcher A, Forette F, Goldhaber A, Palatini P, Sarti C, Fagard R. Effect of calcium-channel blockade in older patients with diabetes and systolic hypertension. N Engl J Med1999; 340:677–84.
17. Fletcher AE, Bulpitt CJ. Epidemiological aspects of cardiovascular disease in the elderly. J Hypertens1992; 10:S51–8.
18. Bulpitt CJ, Fletcher AE, Amery A, Coope J, Evans JG, Lightowlers S, O'Malley K, Palmer A, Potter J, Sever P, Staessen J, Swift C. The Hypertension in the Very Elderly Trial (Hyvet): Rationale, methodology and comparison with previous trials. Drugs Aging1994; 5:171–83.[ISI][Medline]
19. Gueyffier F, Bulpitt CJ, Boissel JP, Schron E, Ekbom T, Fagard R, Casiglia E, Kerlikowse K, Coope J, for the INDANA Group. Antihypertensive drugs in the very old people: a subgroup meta-analysis of randomised controlled trials. Lancet1999; 353:793–6.[ISI][Medline]
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  O.M.P. Jolobe Controlling hypertension in the elderly QJM, October 1, 2000; 93(10): 700 - 701. [Full Text]
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||